Mutation Detection – Highly sensitive detection of gene modifications/mutations

articularly in oncology determination of gene mutation statuses serve as a biomarker to guide therapeutic decisions.
Scientists of the University of Duisburg-Essen developed an RT-PCR based test, with a sensitivity of up to 0.005% against a background of wild type alleles, detecting deletions and insertions as well as point mutations. The assay is robust and applicable in a broad range of laboratories.
So far current methods for screening the epidermal growth factor-receptor (EGFR)-gene in patients with non-small lung cancer (NSCLC) require taking tumor biopsies. By applying this sensitive technology, it is possible to detect even one single mutated circulating tumor (CTC) cell per milliliter peripheral blood. As sequential biopsies or biopsies of multiple tumor lesions are not routinely performed due to patient safety, this opens new non-invasive possibilities for monitoring the mutation status of patients during treatment and to detect disease relapse early.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

As Germany’s association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Quelle: TechnologieAllianz e.V.
Weitere Informationen: www.technologieallianz.de/angebote.php?sort=sag&id=2954&lang=en
www.technologieallianz.de